(NASDAQ: CASI) Casi Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.75%.
Casi Pharmaceuticals's earnings in 2025 is -$40,480,000.On average, 1 Wall Street analyst forecast CASI's earnings for 2025 to be -$32,069,643, with the lowest CASI earnings forecast at -$32,069,643, and the highest CASI earnings forecast at -$32,069,643. On average, 1 Wall Street analyst forecast CASI's earnings for 2026 to be -$25,252,907, with the lowest CASI earnings forecast at -$25,252,907, and the highest CASI earnings forecast at -$25,252,907.
In 2027, CASI is forecast to generate -$24,633,204 in earnings, with the lowest earnings forecast at -$24,633,204 and the highest earnings forecast at -$24,633,204.